Oceanographers study the impact of toxic ash from the L.A. wildfires
Recently, the ship was traveling the coast collecting plankton samples, small organisms that many larger fish live on. But this trip was anything but ordinary.
"This is something I've never experienced before, and I don't know anybody else that has," Scripps Institute scientist Dr. Rasmus Swalethorp told CBS News.
What the researchers experienced, by total coincidence, was pulling up to Los Angeles in January as the deadly and devastating Palisades and Eaton fires were burning thousands of homes, incinerating plastic, paint, asbestos and car batteries. The fires released a cloud of toxic ash that settled over the ocean for about 100 miles.
Crew members put on masks to protect against the smoke as black ash settled on the ship, while the plankton they collected was also swimming in ash.
"All the organisms that are going to live down on the seabed, they're certainly going to be exposed to this, potentially transporting whatever is in that ash further up the food chain," Swalethorp said.
Scientists with the Scripps Institute have been collecting California ocean samples for 75 years. The new ash-laden samples will be added to this vast archive.
"We know what the fish are like under normal circumstances, but the scientific opportunity here is to look at the condition of the fish when they're exposed to all the ash," said Andrew Thompson, a scientist with the National Oceanic and Atmospheric Administration.
Commercial and recreational fishing in California brings in about $1 billion a year and supports 193,000 full and part-time jobs, according to numbers from the NOAA. While it could take years to know how, or if, these toxins impact fish, both fishermen and restaurants say knowing the answer is important.
"The damage that these fires has caused is like woven so deeply into the fabric of our food systems that it's something that you know, it should be just an absolute red flag for anyone involved…a red flag for change," said Michael Cimarusti, a chef at the L.A. seafood restaurant Providence. "Like, what can be done to ensure that these kinds of fires, like, don't happen again."
Swalethorp says monitoring how ocean life responds will continue for years.
"We are also going to be looking for chromium, for mercury," Swalethorp said. "…Things we don't want in the ocean."
But because of a grim kind of luck, scientists at least have a head start in knowing exactly what toxins they are looking for.
Dolly Parton's husband, Carl Dean, died at age 82. Here's a look back at their love story
Federal employees received a new email about weekly tasks. Here's how agencies responded.
"Anora" wins 5 Oscars at 97th Academy Awards
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Advancing rare disease trials by overcoming patient recruitment challenges
Next month, clinical development and clinical operations professionals will gather and discuss the current challenges in running clinical trials for orphan drugs and rare diseases at the 3rd Annual Clinical Trials in Rare Diseases (CTRD) meeting in Princeton, New Jersey. The meeting, which will take place 17–18 September, will bring together experts from the pharmaceutical and biotech sectors to discuss, not only the obstacles and solutions to clinical trial operational issues, but also to explore the evolving landscape of clinical trials for rare diseases, with a strong emphasis on innovation, collaboration, and patient-centric approaches. At the same venue, the 3rd Annual Clinical Data Management Innovation (CDMI) will explore ways to streamline data entry and collection at trial sites, make better use of real-world evidence, and address the evolving regulatory environment around clinical data. Both meetings will run in parallel at the same venue in Princeton, New Jersey. The Clinical Trials in Rare Diseases meeting will kick off with a case study on how artificial intelligence (AI) is accelerating rare disease drug development. During the talk, Bruce Bloom, CEO of Fortuity Pharma, will map out processes for pre-IND packages, working with the US Food and Drug Administration (FDA), and explore both the challenges and successes of applying AI in such trials. At the CDMI conference, a keynote by Jeff Malavasi, Associate Director of Information Security and Data Compliance of the Cambridge, Massachusetts-based biotech Scholar Rock, will focus on the growing cybersecurity challenges created by the digital transformation of clinical trials. His talk will also provide a practical framework for adopting AI-driven security solutions, including zero-trust architectures and automated response protocols, to safeguard sensitive clinical data. Building on the theme of AI, Aamir Jaka, Global Vice President of the clinical analytics company Saama, will laterexplore how agentic AI is moving data management beyond traditional rule-based automation. Patient recruitment is a persistent challenge in rare disease research On the same day, Jamie Switzer, Associate Director of Clinical Operations at Insmed, will present a case study on strategies to keep trials on schedule while tackling the issue of patient recruitment. Earlier this month, Insmed's drug Brinsupri (brensocatib) was approved to treat non-cystic fibrosis bronchiectasis by the FDA based on results from the Phase III ASPEN (NCT04594369) and Phase II WILLOW (NCT03218917) studies. Switzer will provide practical solutions to patient recruitment problems, while a subsequent panel discussion featuring industry leads from Alexion, Insmed, Asklepion Pharmaceuticals, and BioMarin will take the conversation further to discuss innovative ways to engage patients. Patient recruitment and patient advocacy will be a recurring theme throughout the conference, with speakers sharing insights and emphasising the importance of having patient advocacy organisations as an indispensable partner to extend trial reach, co-design protocols, and foster genuine patient-centered practices. Patient centricity will also be a key theme in the CDMI meeting, where Dinesh Pillaipakkamnatt, former Director of Merck & Co, will highlight how to create a more personalised trial experience, while also considering data privacy, adoption barriers, and the safe handling of large volumes of sensitive information. Tackling operational challenges with clinical trials The second day of both meetings will commence with interactive roundtable discussions on topics such as importance of decentralising rare disease trials, strategies to overcome patient retention barriers, best practices for managing external data and addressing issues of identity, integration, and privacy while enabling patient-centric data management, across both the conferences. The patient and caregiver perspective with rare disease research will be explored with Leigh Dallow, Patient Advocate & Caregiver, sharing her experience around trial participation, discussing trial enrollment decisions, and patient burden, in the CTRD meeting. In a subsequent session, an expert from the Rare Disease Diversity Coalition will discuss the issues of inclusion and diversity in rare disease trials, focusing on underrepresented populations and ways to ensure fair access to therapies and research opportunities. In the afternoon, the focus will shift to the strategic and operational elements of rare disease drug development. In a fireside chat, Bloom and Paul Lupo of PTC Therapeutics will discuss issues such as how to select a CRO and how to work with small patient populations. Another fireside chat, led by Kinjal Patel and Janine Sampong, both with Mitsubishi Tanabe Pharma America, will examine how to accelerate timelines when working with clinical sites and propose strategies to attract attention of academic organisations, and build strong partnerships. Concurrently, the second day of the CDMI meeting will feature several sessions on successful strategies for CDM vendor selection and outsourcing models, an important update on ICH E6(R3) guidelines and its implications for clinical data management, and the implications of AI and machine learning for clinical data management. The meeting will conclude with a case study on CRO and sponsor collaboration, emphasising the importance of improving partnerships and aligning financial incentives. The 3rd Annual Clinical Trials in Rare Diseases and the 3rd Annual Clinical Data Management Innovation conferences are hosted by Arena International Events Group, a B2B events company owned by GlobalData, the parent company of Clinical Trials Arena and Pharmaceutical Technology. Click here to read the agenda for the conference for 3rd Annual Clinical Trials in Rare Diseases and the 3rd Annual Clinical Data Management Innovation. "Advancing rare disease trials by overcoming patient recruitment challenges" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Space Force Launching Secretive Experimental Spacecraft With Quantum Equipment on Board
Quantum of Orbit Less than six months after concluding a year-plus mission in orbit, the Space Force's top-secret X-37B space plane is gearing up for its eighth mission in just over 15 years. As the Orlando Sentinel reports, the enigmatic, Boeing-built spacecraft is set to launch from the Kennedy Space Center's historic Launch Pad 39A later this evening, carrying some intriguing-sounding scientific equipment with it into orbit. The Space Force, in collaboration with the Air Force's Rapid Capabilities Office, is testing out the "highest performing quantum inertial sensor ever tested in space," according to a Boeing press release. "The revolutionary quantum inertial sensor will demonstrate precise positioning, navigation, and timing in a GPS-denied environment." In other words, if GPS satellites were ever to be targeted by an adversary — a growing concern, according to the US military — or go down due to other hazards such as space junk, the US military is looking for backup ways to navigate the vastness of outer space. "Whether navigating beyond Earth-based orbits in cis-lunar space or operating in GPS-denied environments, quantum inertial sensing allows for robust navigation capabilities where GPS navigation is not possible," said Space Delta 9 commander colonel Ramsey Hom in the press release. Major Laser Apart from the quantum sensor, the X-37B spacecraft will also be demonstrating "high-bandwidth inter-satellite laser communications technologies," which could "strengthen the resilience, reliability, adaptability, and data transport speeds of our satellite communications architectures," according to US Space Force chief of space operations Chance Saltzman. While many aspects of its top-secret missions remain shrouded in mystery, Boeing's X-37B has become an integral part of the Pentagon's efforts to conduct high-tech experiments in space. That's especially important as the International Space Station readies itself to be retired by the end of the decade, giving the US no permanent foothold in Earth's orbit to conduct science in the absence of a privately funded and developed alternative. The X-37B also represents a point of pride for Boeing, whose astronaut-ferrying spacecraft Starliner has been mired in problems and remains a major headache for both the aerospace company and NASA. More on the spaceplane: Mysterious Spacecraft Lands at Space Force Base
Miami Herald
5 hours ago
- Miami Herald
100-year-old creatures at PA zoo welcome 9 babies. See the couple's rare brood
The Philadelphia Zoo is celebrating a big moment for an almost-extinct reptile species: the hatching of nine critically endangered Western Santa Cruz Galapagos tortoises. The babies will join their seven siblings, which hatched earlier this year. All 16 were parented by Abrazzo and Mommy, the zoo said in an Aug. 20 Instagram post. 'These nine hatchlings — six males and three females — are the second ever clutch of this species to hatch in Philadelphia Zoo's history,' the zoo said. 'These offspring join seven others that hatched earlier this year and made Mommy the oldest first-time mom of her species. Mommy and their dad, Abrazzo, are both nearly 100 years old! The hatchlings are spending time in their habitat inside the Reptile and Amphibian House, in their outdoor habitat near the building, and behind the scenes.' According to CBS News, with the addition of the 16 hatchlings, the total of the rare tortoises now under human care in North America is up to 60. Mommy came to the zoo in 1932 but had never bred until Abrazzo was brought in from Columbia, South Carolina, in 2020, ABC News said. 'Now this animal, who's been in Philadelphia since 1932, will be represented here for, hopefully, another 100 years because her offspring are now part of our collection,' Lauren Augustine, the zoo's director of herpetology, told ABC. These specific tortoises are found in the wild on the Galapagos Islands and can grow to between 250 and 500 pounds. 'Scientists estimate they can live between 100-200 years old. There are currently 13 living species that are native to seven of the islands,' the Philadelphia Zoo said.
